Search results for PX-TA1369

Evinacumab Biosimilar – Anti-ANGPTL3 mAb – Research Grade, ProteoGenix, PX-TA1369

Description of Evinacumab Biosimilar - Anti-ANGPTL3 mAb - Research Grade General information on Anti-ANGPTL3[Homo sapiens] (Evinacumab) Monoclonal Antibody Evinacumab is a recombinant human IgG4 monoclonal antibody targeting human angiopoietin-like protein 3 (ANGPTL3). The ANGPTL protein family has many physiological functions-including the regulation of lipid metabolism. It has been noted that the loss-of-function mutation of ANGPTL3 leads to hypolipidemia and subsequently reduces cardiovascular risk, while increased function seems to be related to cardiovascular risk. Evinacumab has been used to treat homozygous familial hypercholesterolemia (HoFH). It has been sold under the Evkeeza brand name.